VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Immune dysregulation in myeloma and impact on disease progression

David Avigan, MD, Harvard Medical School, Boston, MA, briefly discusses the importance of investigating immune dysregulation in patients with multiple myeloma, highlighting the role of T-cell exhaustion and how this may impact disease progression. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter